ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the glob

Investors need to pay close attention to PODD stock based on the movements in the options market lat

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Insulet (PODD) reached a significant support level, and could be a good pick for investors from a te

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the glob

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

Deutsche Bank analyst Kieran Ryan initiates coverage on Insulet (NASDAQ:PODD) with a Buy rating a

Truist Securities analyst Richard Newitter maintains Insulet (NASDAQ:PODD) with a Buy and lowers

STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across ag

U.S. tech stocks plunged more than 3% by midday Friday after a hotter-than-expected jobs report fuel

https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-insulin-pump

Presentations will feature next generation Omnipod innovations designed to reduce user effort, new a

Enhanced algorithm with new 100 mg/dL Target Glucose and improved alarm handling helps users improve

Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Neutral and lowers the pr

Dow notches fresh all-time high while Nasdaq 100 drops 0.7% as chip stocks unwind. Oil sinks nearly

RBC Capital analyst Shagun Singh reiterates Insulet (NASDAQ:PODD) with a Outperform and maintains

Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Gro

Wall Street analysts changed outlook on top stocks. Check analyst ratings page for all changes, inc

BTIG analyst Marie Thibault maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price targe

Insulet Corporation, Inc. (NASDAQ:PODD) ("Insulet" or the "Company") today announced

B of A Securities analyst Travis Steed maintains Insulet (NASDAQ:PODD) with a Buy and lowers the

Barclays analyst Matt Miksic maintains Insulet (NASDAQ:PODD) with a Underweight and lowers the pr

Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and lowers

JP Morgan analyst Robbie Marcus maintains Insulet (NASDAQ:PODD) with a Overweight and lowers the

RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the

Truist Securities analyst Richard Newitter maintains Insulet (NASDAQ:PODD) with a Buy and lowers

Evercore ISI Group analyst Daniel Markowitz maintains Insulet (NASDAQ:PODD) with a Outperform and

Wells Fargo analyst Lawrence Biegelsen maintains Insulet (NASDAQ:PODD) with a Overweight and lowe

Bernstein analyst Lee Hambright maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the

Oppenheimer analyst Suraj Kalia maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the

BTIG analyst Marie Thibault maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price targe

U.S. stocks hit records as Trump's Iran memo sinks oil 6%, AMD soars 17% on data-center beat.

Insulet (PODD) beats Q1 expectations with $1.42 EPS and $761.7M revenue. Omnipod growth drives a rai

Insulet (NASDAQ:PODD) FY2026 expected to be more than $6.21 vs $6.36 Est. raises FY2026 sales outlo

Insulet (NASDAQ:PODD) reported quarterly earnings of $1.42 per share which beat the analyst consensu

First participant enrolled in randomized control trial designed to demonstrate safety and efficacy o

FDA flags serious recall of Insulet's Omnipod 5 Pods over insulin delivery risk; 476 injuries re

https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/insulin-pump-recall-insu

https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/insulin-pump-recall-insu

Cramer suggests buying MP Materials instead of Critical Metals Corp. Rivian Automotive partners with

Morgan Stanley downgraded FCX and Raymond James downgraded IRDM, while MoffettNathanson downgraded D

Benzinga analysts changed outlook on top names. For all rating changes, incl upgrades/downgrades, se

MiniMed shows improved pipeline and valuation upside as insulin pump adoption grows despite rising c

Women remain scarce in the C‑suite, with only a fraction of large U.S. companies led by female CEOs.

Insulet shares fall after the company warns certain Omnipod 5 Pods may under-deliver insulin, linked

Major Wall Street indexes were slightly higher by midday Friday, supported by economic data that str